Open AccessThis article is
- freely available
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Endocrinology, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro 88100, Italy
* Author to whom correspondence should be addressed.
Received: 1 October 2013; in revised form: 30 October 2013 / Accepted: 8 November 2013 / Published: 20 November 2013
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Several lines of evidence have indicated a pathogenic role of insulin resistance, and a strong association with type 2 diabetes (T2MD) and metabolic syndrome. Importantly, NAFLD appears to enhance the risk for T2MD, as well as worsen glycemic control and cardiovascular disease in diabetic patients. In turn, T2MD may promote NAFLD progression. The opportunity to take into account NAFLD in T2MD prevention and care has stimulated several clinical studies in which antidiabetic drugs, such as metformin, thiazolidinediones, GLP-1 analogues and DPP-4 inhibitors have been evaluated in NAFLD patients. In this review, we provide an overview of preclinical and clinical evidences on the possible efficacy of antidiabetic drugs in NAFLD treatment. Overall, available data suggest that metformin has beneficial effects on body weight reduction and metabolic parameters, with uncertain effects on liver histology, while pioglitazone may improve liver histology. Few data, mostly preclinical, are available on DPP4 inhibitors and GLP-1 analogues. The heterogeneity of these studies and the small number of patients do not allow for firm conclusions about treatment guidelines, and further randomized, controlled studies are needed.
Keywords: nonalcoholic fatty liver disease (NAFLD); insulin resistance; type 2 diabetes mellitus (T2DM); cardiovascular disease (CVD); antidiabetic drugs; statins
Citations to this Article
Cite This Article
MDPI and ACS Style
Fruci, B.; Giuliano, S.; Mazza, A.; Malaguarnera, R.; Belfiore, A. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. Int. J. Mol. Sci. 2013, 14, 22933-22966.
Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. International Journal of Molecular Sciences. 2013; 14(11):22933-22966.
Fruci, Barbara; Giuliano, Stefania; Mazza, Angela; Malaguarnera, Roberta; Belfiore, Antonino. 2013. "Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment." Int. J. Mol. Sci. 14, no. 11: 22933-22966.